Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

In Vitro and In Vivo Evaluations of the Metabolism, Pharmacokinetics, and Bioavailability of Ester Prodrugs ofl-767,679, A Potent Fibrinogen Receptor Antagonist

An Approach for the Selection of a Prodrug Candidate

Thomayant Prueksaritanont, Lynn M. Gorham, Michael J. Breslin, John H. Hutchinson, George D. Hartman, Kamlesh P. Vyas and Thomas A. Baillie
Drug Metabolism and Disposition August 1997, 25 (8) 978-984;
Thomayant Prueksaritanont
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn M. Gorham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Breslin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John H. Hutchinson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George D. Hartman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamlesh P. Vyas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas A. Baillie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

An Approach for the Selection of a Prodrug Candidate

Abstract

The present study demonstrates the utility of an in vitro–in vivo correlative approach in the selection of an optimum prodrug candidate of l-767,679 (N-{[7-(piperazin-1-yl)-3,4-dihydro-1(1H)-isoquinolinone-2-yl]acetyl}-3(S)-(ethynyl)-β-alanine), a potent fibrinogen receptor antagonist. As an initial screening step, a comparative in vitro hepatic metabolism study was conducted for l-767,679 and a series of aliphatic and aromatic ester prodrugs in dogs, monkeys, and humans. In all species, the active acid l-767,679, but not the ester prodrugs, was resistant to metabolism. Only the methyl, ethyl, and isopropyl esters were converted exclusively to the active acid in liver microsomal preparations from dogs and humans, and thus were selected for further studies. In the preparations from monkeys, all of the esters investigated were metabolized efficiently to both the active acid and several other products. The absolute formation rates ofl-767,679 from the esters followed the rank order: methyl ∼ ethyl > isopropyl in all species, and in humans > dogs for the three esters. The three ester prodrugs did not undergo appreciable hydrolysis in blood or upon incubation with intestinal S9 from any of the studied species.

In vivo evaluation of the previous three aliphatic esters in dogs and monkeys supported the in vitro findings.l-767,679 was metabolically stable in both dogs and monkeys. After intravenous administration of the prodrugs to either species, the extent of acid formation was higher in dogs than in monkeys. In addition, the extent of l-767,679 formed from these prodrugs followed the rank order: methyl ∼ ethyl > isopropyl. Similar results were obtained after oral dosing of the prodrugs, such that the bioavailability of l-767,679 was higher in dogs than in monkeys, and the bioavailability was higher after the ethyl ester than after the isopropyl prodrug in both species. In either species, both ethyl and isopropyl ester prodrugs were better absorbed than l-767,679.

Overall, the results suggested that the bioavailability of the active acid after administration of an ester prodrug was dictated primarily by two factors, viz.: 1) the relative rates of ester hydrolysis versus competing metabolic reactions and2) the absolute rates of ester hydrolysis. In the case ofl-767,679 prodrugs, absorption was not a limiting factor. Consequently, the bioavailability of l-767,679 after oral administration of the ester prodrugs would likely be greater in humans than in dogs, and in humans would be higher with the ethyl ester than with the isopropyl ester. On this basis, the ethyl ester was considered as a promising candidate for clinical evaluation as a fibrinogen receptor antagonist prodrug.

Footnotes

  • Send reprint requests to: Dr. Thomayant Prueksaritanont, Department of Drug Metabolism, WP 26A-2044, Merck Research Laboratories, West Point, PA 19486.

  • ↵2 L. M. Gorham and T. Prueksaritanont, manuscript in preparation.

  • Abbreviations used are::
    F
    oral bioavailability of the administered compound
    iv
    intravenous
    po
    per oral
    UDPGA
    uridine diphosphate glucuronic acid
    CLint
    intrinsic clearance
    F679 (prodrug iv)
    bioavailability ofl-767,679 after intravenous administration of a prodrug
    F679 (prodrug po)
    oral bioavailability ofl-767,679 after oral administration of a prodrug
    AUC0-inf
    area under the plasma concentration-time curve from time 0 to infinity
    t1/2
    half-life
    • Received February 14, 1997.
    • Accepted April 16, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 25, Issue 8
1 Aug 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro and In Vivo Evaluations of the Metabolism, Pharmacokinetics, and Bioavailability of Ester Prodrugs ofl-767,679, A Potent Fibrinogen Receptor Antagonist
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

In Vitro and In Vivo Evaluations of the Metabolism, Pharmacokinetics, and Bioavailability of Ester Prodrugs ofl-767,679, A Potent Fibrinogen Receptor Antagonist

Thomayant Prueksaritanont, Lynn M. Gorham, Michael J. Breslin, John H. Hutchinson, George D. Hartman, Kamlesh P. Vyas and Thomas A. Baillie
Drug Metabolism and Disposition August 1, 1997, 25 (8) 978-984;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

In Vitro and In Vivo Evaluations of the Metabolism, Pharmacokinetics, and Bioavailability of Ester Prodrugs ofl-767,679, A Potent Fibrinogen Receptor Antagonist

Thomayant Prueksaritanont, Lynn M. Gorham, Michael J. Breslin, John H. Hutchinson, George D. Hartman, Kamlesh P. Vyas and Thomas A. Baillie
Drug Metabolism and Disposition August 1, 1997, 25 (8) 978-984;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Determination of Acyl-, O-, and N-Glucuronide
  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics